top of page
Search by
Poster Number
1, 2, 3, 4,
5, 6, 7, 8,
9, 10, 11, 12,
13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
Click on the Poster to View the Poster Page
POSTER 1
Evaluation of Risk of Formation of Atrophic Acne Scars During Acne Treatment with Trifarotene 50μg/g Cream versus Vehicle Cream: Results...
POSTER 2
Efficacy and Safety of Trifarotene Cream 50µg/g for the Treatment of Acne-Induced Post-Inflammatory Hyperpigmentation in Subjects with...
POSTER 3
Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Acne: Pooled Analysis by Age and Sex Julie C. Harper, MD;...
POSTER 4
Early and Sustained Effects of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel Leon H. Kircik, MD; Edward (Ted)...
POSTER 5
Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel to Treat Acne Induced by Janus Kinase Inhibitor Treatment: A Case...
POSTER 6
Safety and Tolerability of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Truncal Acne Leon H. Kircik, MD; Julie C....
POSTER 7
The Efficacy and Safety of Clascoterone Cream 1% for the Treatment of Acne Vulgaris Are Not Dependent on Patient Age and Sex: Results of...
POSTER 8
Efficacy and Safety of Clascoterone Cream 1% in Patients with Acne with Skin of Color: 16-Week Interim Analysis Leon Kircik, Susan C....
POSTER 9
Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata (AA): 3-Year Results from the ALLEGRO-LT...
POSTER 10
Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months in Patients with Alopecia Areata (AA) from the ALLEGRO Clinical Trial...
POSTER 11
Timing of Initial Hair Regrowth and Clinical Trial-Defined Response following Ritlecitinib Treatment in Patients with Alopecia Areata...
POSTER 12
Change in Patient-Reported Hair Satisfaction During Deuruxolitinib Treatment of Severe Alopecia Areata: Pooled Data from the Phase 3...
POSTER 13
Improvement in Anxiety and Depression in Adult Patients with Severe Alopecia Areata Treated with Deuruxolitinib: Pooled Data from the...
POSTER 14
INTEGUMENT-INFANT: A Phase 2, 4-Week Open-Label Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less than 2 Years Old...
POSTER 15
Tapinarof Cream 1% Once Daily: Maintenance of Low Disease Activity Including Pruritus Through End of the Treatment-free Interval in a...
POSTER 16
Real-World Insights on Systemic Treatments and Disease Control in Atopic Dermatitis: Patient Satisfaction and Recap of Atopic Eczema...
POSTER 17
Patients Maintain Stable Response with No or Minimal Fluctuations during 3 Years of Continuous Treatment with Lebrikizumab during...
POSTER 18
Long-term Efficacy and Safety of Lebrikizumab Is Maintained in Patients with Moderate-to-Severe Atopic Dermatitis: Results Up to 3 Years...
POSTER 19
Lebrikizumab Improves Atopic Dermatitis in Patients with Limited Skin Involvement and High Itch Shawn Kwatra, Thomas Werfel, Martin...
POSTER 20
Nemolizumab Long-Term Safety and Efficacy up to 104 Weeks in the ARCADIA Open-Label Extension Study in Adolescents and Adults with...
POSTER 21
Long-Term Safety and Disease Control of Ruxolitinib Cream in Children Aged 2 to 6 and 7 to 11 Years With Atopic Dermatitis: Results From...
POSTER 22
Real-World Effectiveness of Tralokinumab in Adults with Atopic Dermatitis: Interim Data on Improvements in Patients with Head and Neck...
POSTER 23
Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab Matthias...
POSTER 24
Long-Term Safety and Efficacy of Tralokinumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Treated for Up to 6...
POSTER 25
Treatment-Free Disease Control After Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Andrew Blauvelt, Tina Bhutani,...
POSTER 26
Combined Skin Clearance and Quality of Life Response in Patients With Moderate-to-Severe Atopic Dermatitis With and Without Prior...
POSTER 27
Impact of Baseline Disease Severity on the Long-Term Efficacy and Safety of Abrocitinib Treatment in Adolescent Patients With...
POSTER 28
Effect of Abrocitinib and Dupilumab on the Incidence of Conjunctivitis in Patients With Atopic Dermatitis: An Analysis of Abrocitinib...
POSTER 29
Maintenance of Optimal Response Over 2 Years in Patients With Atopic Dermatitis Treated With Dupilumab Thomas Bieber, Eric L. Simpson,...
POSTER 30
Dupilumab Safety and Efficacy Up To 3 Years in Children Aged 6 Months to 11 Years with Atopic Dermatitis Amy S. Paller, Eric L. Simpson,...
POSTER 31
Dupilumab Monotherapy Prevents Flares and Provides Sustained Control of Atopic Dermatitis Over 1 Year Across Various Dose Regimens Eric...
POSTER 32
Sustained Disease Control Among Adults with Moderate-to-Severe Atopic Dermatitis in Clinical Practice: 5-Year Follow-up Results From the...
POSTER 33
Dupilumab Treatment Reduces Medium- and High-Potency Topical Corticosteroid Usage in Pediatric Patients Aged 6 Months to 5 Years With...
POSTER 34
Dupilumab Reduces Severity and Lesion Extent in Children <12 Years with Moderate-to-Severe AD: 4-Year Results from the PEDISTAD Registry...
POSTER 35
Dupilumab Efficacy in Pooled LIBERTY-CSU CUPID Study A and Study C Regardless of Baseline Total Serum IgE Levels Sarbjit S. Saini, MD,...
POSTER 36
Kyrle's Disease: Dermatologic Manifestations of Systemic Disease Jung Sung, MS, PA; Curt Samlaska, MD < Previous Poster | Next Poster >...
POSTER 37
“Super-Response” Following Treatment with Delgocitinib Cream 20 mg/g in a Subgroup of Patients with Moderate to Severe Chronic Hand...
POSTER 38
Matching-Adjusted Indirect Comparison of the Efficacy of Delgocitinib and Dupilumab in the Treatment of Moderate to Severe Atopic Hand...
POSTER 39
Delgocitinib Cream 20 mg/g in Chronic Hand Eczema Patients with Skin Fissures: Efficacy, Safety, and Pharmacokinetics Lawrence F...
POSTER 40
Delgocitinib Cream Has Negligible Systemic Exposure in Patients with Maximal Use of Delgocitinib Cream for the Treatment of Chronic Hand...
POSTER 41
Delgocitinib Cream Provides Early and Meaningful Responses in Adults with Moderate to Severe Chronic Hand Eczema: A Pooled Analysis of...
POSTER 42
Dupilumab Provides Early and Sustained Improvement in Itch in Patients With Chronic Spontaneous Urticaria: Pooled Results From...
POSTER 43
Efficacy and Safety of Deucravacitinib in Patients With Discoid Lupus Erythematosus (DLE) and/or Subacute Cutaneous Lupus Erythematosus...
POSTER 44
Daily Use of a Novel Cream Improves Thinning, Pre-Dermatoporosis Skin Alan Widgerow, MBBCh, MMed, FCS, FACS; Sarah Anjuwon, Mathieu...
POSTER 45
Bimekizumab Impact on Flare in Hidradenitis Suppurativa Over 2 Years: Data from BE HEARD EXT Haley B. Naik, Steven Daveluy, Errol Prens,...
POSTER 46
Use of Non-Prescription Topical Nitric Oxide Releasing Preparations for Dermatological Infections Gilly Regev, PhD; Chris Miller, PhD <...
POSTER 47
A Non-Prescription Nitric Oxide Releasing Gel Demonstrates In Vitro Anti-Fungal Activity and Supports Nail Clearance in Patients with...
POSTER 48
Avapritinib Durably Improves Cutaneous Involvement of Indolent Systemic Mastocytosis in Patients Treated in the PIONEER Study Frank...
POSTER 49
Thiamidol (isobutylamido thiazolyl resorcinol): A Highly Specific Human Tyrosinase Inhibitor for the Treatment of Hyperpigmentation...
POSTER 50
Clinical Efficacy of the Human Tyrosinase Inhibitor Thiamidol (isobutylamido thiazolyl resorcinol) in Melasma Dennis Roggenkamp, Adel...
bottom of page